Tali Digital Ltd · ASX:TD1
Tali Digital — Investor Presentation (December 2020)
41 slides from Tali Digital's investor presentation, Dec 10, 2020
Slide 1: TALi Digital Investor Presentation December 2020
For personal use only TALi DIGITAL (ASX: TD1) Investor Presentation December 2020 Happier kids start here. talidigital.com
Slide 2: Digital Therapeutics for Cognitive Function
For personal use only Digital Therapeutics for Cognitive Function. TALi DIGITAL (ASX: TD1) Investor Presentation | December 2020 | 2
Slide 3: World's first personalised digital test and treatment platform for early childhood attention
The world’s first personalised digital test and treatment platform for early childhood attention For personal use only Novel technology platform Clinically validated Partnerships secured Game-based digital programs supported by Supported by 25+ years of research in Partner status secured with Google
Slide 4: TALi TRAIN: Patented global medical device
TALi TRAIN For personal use only Patented global medical device. Registered in the USA (FDA) Registered in Australia (TGA) Registered in the EU (CE) Patents in the US and in Japan with applications pending review in other jurisdictions. TALi’s plus trademarks are registered in the US, Canada, EU, an
Slide 5: The market opportunity
For personal use only The market opportunity Global problem, global market. TALi DIGITAL (ASX: TD1) Investor Presentation | December 2020 | 5
Slide 6: Cognitive impairments are a key global health issue
Cognitive impairments are a key global health issue For personal use only 136 million $20 billion 32% children in costs per year growth rate $ A global issue¹ The cost of inattention² Growth in the market³ Globally, 136 million children are identified Attention-related disorders (including Cognitive
Slide 7: Our roadmap | In-market
Our roadmap | In-market For personal use only Early childhood: The best time to target cognitive skills of attention. Early Childhood check-circle Screen for low attention skills, TALi which may be an indicator of DETECT disorders such as ASD and ADHD check-circle Strengthen cognitive attention TALi
Slide 8: Our roadmap | Expansion
Our roadmap | Expansion For personal use only Areas of opportunity: Leveraging the core patented technology for use in novel populations. Teenage Years and Adulthood Elderly Years check-circle Screen for indicators of attention- check-circle Screen for indicators Assessment related disorders such as
Slide 9: TALi's vision to improve detection and support for cognitive function
TALi’s vision is to improve the detection & support for cognitive function For personal use only Targeted treatment strategies Remote monitoring Clinically validated Enable targeted treatment strategies Support remote monitoring of digital Improve patient safety and drug management. and precision me
Slide 10: A practical, affordable tool
For personal use only A practical, affordable tool TALi’s digital treatment is part of the solution. TALi DIGITAL (ASX: TD1) Investor Presentation | December 2020 | 10
Slide 11: Evidence-based digital tool
Evidence-based digital tool For personal use only TALi has developed an evidence based digital health platform that makes a real difference in the lives of children with attention and learning difficulties. The technology combines 25+ years of research in developmental psychology and cognitive neuro
Slide 12: Early intervention makes a significant impact
Early intervention makes a significant impact For personal use only The earlier TALi works with children aged 3 – 8 years. the investment, Rate of Return to Investment in Human Capital the greater Prenatal programs the return. Programs targeted toward the early years Rate of Return to Investment in
Slide 13: Delivered via smartphone or tablet devices
TALi — delivered via smartphone or tablet devices. For personal use only TALi DETECT Access via initial assessment through one-off payment. TALi TRAIN Access via 25 x 20min sessions through one-off payment or volume price point for B2B customers. TALi MAINTAIN Planned access via twelve month “booste
Slide 14: Attention profile and real-time status reports
Attention profile and real-time status reports For personal use only TALi Reports Evidence-based algorithms produce a detailed summary of attention-based and activities-based performance across three different domains of cognitive attention. The results are benchmarked against a standard deviation c
Slide 15: Dashboard to manage assessment and training data
Dashboard to manage assessment and training data For personal use only TALi Portal Assessment, compliance and progression data sets are accessible via the TALi Portal by administrators of the program. Accessibility and administration capabilities customisable for large institutions and networks. TAL
Slide 16: TALi DETECT
TALi DETECT For personal use only TALi DETECT reports have been designed to provide a data driven, baseline assessment of a child’s core cognitive skills — and it only takes 20 minutes. On Track Monitor Prompt Performing at or above the expected level. Slightly lower attention skills than average. L
Slide 17: TALi DETECT: evidence shows it can be the new clinical standard
TALi DETECT Evidence shows TALi DETECT can be the new clinical standard. For personal use only TALi DETECT Initial results highlight Validity DETECT TEA-CH2 J Strength of program works in a Using Structural equation modelling (SEM), it was confirmed that DETECT Result game game correlation real-life
Slide 18: TALi TRAIN: exercising core attention skills
TALi TRAIN For personal use only TALi TRAIN Exercising core attention skills TALi TRAIN consists of 25 x 20-minute sessions, conducted over a five-week period. The four exercises per session target skills observed to be Selection Focus impaired in neurodiverse children. As the child Selective Attent
Slide 19: Clinical evidence shows TALi TRAIN creates sustained benefits
TALi TRAIN Clinical evidence shows TALi TRAIN creates sustained benefits. For personal use only TALi TRAIN Computerised attention Rationale training for children This study aimed to assess the immediate and long-term efficacy of a Selective Attention Accuracy with intellectual and computerised atten
Slide 20: Clinical evidence shows TALi TRAIN creates sustained benefits
TALi TRAIN Clinical evidence shows TALi TRAIN creates sustained benefits. For personal use only TALi TRAIN Impact of attention training Rationale Numeracy Skills on academic achievement, The aim of this study was to investigate the efficacy of computerised 5 TALi TRAIN executive functioning, and att
Slide 21: Commercial rollout
For personal use only Commercial rollout. TALi DIGITAL (ASX: TD1) Investor Presentation | December 2020 | 21
Slide 22: Commercial rollout: Start local. Go global.
Commercial rollout Start local. Go global. For personal use only Estimated children aged 3 – 8 4.9M 24M children in the UK2 6.1M children in the US1 children in Japan5 149M children in India3 1.9M children in Australia4 1. Source: https://datacenter.kidscount.org/ 2. Source: https://www.statista.com
Slide 23: B2B & B2C in Australia
Commercial rollout | Australia For personal use only B2B & B2C in Australia. Parents Healthcare providers Schools Parents can positively impact their child’s It is clinically proven and well-known Early intervention will present improvements in future development if signs of attention amongst the cl
Slide 24: Commercial rollout | Customer journey
Commercial rollout | Customer journey For personal use only TALi DETECT Assessment results TALi TRAIN Access via initial assessment through Child data is transferred to HCP after Access via 25 x 20min sessions one-off payment. program administrator approval. through one-off payment or volume price p
Slide 25: Partners and providers
Partners and providers For personal use only TALi is working with a range of partners and providers to distribute assessment and training programs to children around the country. Minderoo Foundation is Andrew Forrest’s private foundation. Sonic Learning is a national provider of online training It i
Slide 26: Commercial rollout in India
Commercial rollout | India For personal use only Commercial rollout in India Investment agreement and an advertising agreement with Brand Capital Worldwide Inc. (BCI), the investment company for The Times Group (a Bennett Coleman Company Limited), India’s largest media conglomerate: India’s largest
Slide 27: Deal structure: US$7m total capital investment
Commercial rollout | Deal structure For personal use only US$7m total capital investment US$2m US$5m Tranche 1: Tranche 2: ³ US$2m investment with issue price of ³ Any additional investments by BCI in TALi (up to $US5m) A$0.033 per share, representing the will be at the mutual agreement of both part
Slide 28: International partnership and licensing model
Commercial rollout | International For personal use only International partnership & licensing model. United States Japan UK Seeking partners to roll out TALi under Seeking partners to roll out TALi under Identifying early adopters and KOL’s with a licensing and re-seller model through USA licensing
Slide 29: Google Education Partner Status
International partnership model For personal use only Google Education Partner Status is a significant opportunity for TALi. plus Access TALi via Google products Streamlined with US ed. system Backbone for revenue growth Allows TALi to be accessed via Google Google dominate US ed. system with This p
Slide 30: Revenue model
Revenue model For personal use only Number of children taking TALi DETECT x Cost per test B2C Revenue Number of children taking TALi TRAIN x Cost per training program B2B Revenue Licensing fee + Royalty per child Licensing revenue TALi DIGITAL (ASX: TD1) Investor Presentation | December 2020 | 30
Slide 31: Outlook: Delivering TALi to a million children in three years
For personal use only Outlook Delivering TALi to a million children in three years. TALi DIGITAL (ASX: TD1) Investor Presentation | December 2020 | 31
Slide 32: Outlook: TALi in 2023
Outlook For personal use only 20 23 TALi in 2023 International distribution Government contracts TALi will be used by over one million children Rapid expansion of TALi’s global footprint Long-term sustainability and guaranteed around the world by the end of 2023. will be secured via international pa
Slide 33: Appendix
For personal use only Appendix. TALi DIGITAL (ASX: TD1) Investor Presentation | December 2020 | 33
Slide 34: Practical evidence based improvements
Practical evidence based improvements For personal use only 4087 DETECT assessments completed. 1562 TRAIN programs commenced or completed. 81% 75% of children showing of children showing inattention hyperactivity improvements. improvements. TALi DIGITAL (ASX: TD1) Investor Presentation | December 20
Slide 35: TALi | Board and management
TALi | Board and management For personal use only Sue MacLeman Jefferson Harcourt Dr David Brookes Glenn Smith Non-Executive Chair Non-Executive Director Non-Executive Director Managing Director Sue has more than 30 years’ Mr Harcourt has over 15 years Dr. Brookes has extensive Glenn Smith is an exp
Slide 36: TALi | Advisory Board
TALi | Advisory Board For personal use only Dr Scott Kollins Professor Con Stough Dr Scott Kollins from the Duke University School of Medicine based in Con Stough is a Professor of Cognitive Neuroscience and Psychology the U.S. lends his expertise and thought leadership to support TALi’s at Swinburn
Slide 37: TALi | Advisory Board
TALi | Advisory Board For personal use only Sarah Michel Dr Phil Lambert Sarah Michel, MPH, PMP brings her global experience in the Dr Phil Lambert has extensive experience in education as a teacher, commercialisation of evidence-based health innovations to school principal, inspector, Executive Dir
Slide 38: TALi | Key personnel
TALi | Key personnel For personal use only Pete Saunders Azadeh Feizpour Simone Gindidis Chief Operations Officer Chief Scientific Officer Clinical Lead Pete Saunders works at the intersection of Dr Azadeh Feizpour is a neuroscientist with Dr Gindidis is a psychologist and former experience, data an
Slide 39: TALi | Key personnel
TALi | Key personnel For personal use only Matt Rose Lee Simpson Alex Barty Chief Technology Officer Marketing Manager TD1 Business Development Director Matt Rose is an experienced CTO Lee is a creative and strategic digital marketer, Alex is a graduate of the University of Western and innovator hav
Slide 40: TALi | Financial performance: Capital structure
TALi | Financial performance For personal use only Capital structure ASX code TD1 Share price (as at 8 December 2020) $0.054 per share Number of Shares on issue 749.3 Market capitalisation (as at 8 December 2020) $40.46m Options and warrants on issue - Cash balance (as at 30 September 2020) $2.5m Ma
Slide 41: Happier kids start here
For personal use only Happier kids start here. For further information please contact the TALi Digital team: e. info@talihealth.com | p. 1300 082 013 | w. talidigital.com